576 related articles for article (PubMed ID: 33529600)
21. Metabolic and inflammatory health in SARS-CoV-2 and the potential role for habitual exercise in reducing disease severity.
Marino FE; Vargas NT; Skein M; Hartmann T
Inflamm Res; 2022 Jan; 71(1):27-38. PubMed ID: 34719732
[TBL] [Abstract][Full Text] [Related]
22. Angiotensin II receptors: Impact for COVID-19 severity.
Aksoy H; Karadag AS; Wollina U
Dermatol Ther; 2020 Nov; 33(6):e13989. PubMed ID: 32645228
[TBL] [Abstract][Full Text] [Related]
23. Variants in ACE2; potential influences on virus infection and COVID-19 severity.
Bakhshandeh B; Sorboni SG; Javanmard AR; Mottaghi SS; Mehrabi MR; Sorouri F; Abbasi A; Jahanafrooz Z
Infect Genet Evol; 2021 Jun; 90():104773. PubMed ID: 33607284
[TBL] [Abstract][Full Text] [Related]
24. LTB
Bonyek-Silva I; Machado AFA; Cerqueira-Silva T; Nunes S; Silva Cruz MR; Silva J; Santos RL; Barral A; Oliveira PRS; Khouri R; Serezani CH; Brodskyn C; Caldas JR; Barral-Netto M; Boaventura V; Tavares NM
Diabetes; 2021 Sep; 70(9):2120-2130. PubMed ID: 34417262
[TBL] [Abstract][Full Text] [Related]
25. The triumvirate: why hypertension, obesity, and diabetes are risk factors for adverse effects in patients with COVID-19.
Shah H; Khan MSH; Dhurandhar NV; Hegde V
Acta Diabetol; 2021 Jul; 58(7):831-843. PubMed ID: 33587177
[TBL] [Abstract][Full Text] [Related]
26. Environmental pollution and COVID-19: the molecular terms and predominant disease outcomes of their sweetheart agreement.
Colacci A; Bortone G; Maffei G; Marchesi S; Mescoli A; Parmagnani F; Pillo G; Ranzi A; Rotondo F; Serra S; Vaccari M; Zauli Sajani S; Mascolo MG; Jacobs MN
Epidemiol Prev; 2020; 44(5-6 Suppl 2):169-182. PubMed ID: 33412808
[TBL] [Abstract][Full Text] [Related]
27. The complex combination of COVID-19 and diabetes: pleiotropic changes in glucose metabolism.
Mahrooz A; Muscogiuri G; Buzzetti R; Maddaloni E
Endocrine; 2021 May; 72(2):317-325. PubMed ID: 33886062
[TBL] [Abstract][Full Text] [Related]
28. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.
Senapati S; Banerjee P; Bhagavatula S; Kushwaha PP; Kumar S
J Genet; 2021; 100(1):. PubMed ID: 33707363
[TBL] [Abstract][Full Text] [Related]
29. Susceptibilities of Human ACE2 Genetic Variants in Coronavirus Infection.
Ren W; Zhu Y; Lan J; Chen H; Wang Y; Shi H; Feng F; Chen DY; Close B; Zhao X; Wu J; Tian B; Yuan Z; Zhou D; Saeed M; Wang X; Zhang R; Ding Q
J Virol; 2022 Jan; 96(1):e0149221. PubMed ID: 34668773
[TBL] [Abstract][Full Text] [Related]
30. ACE2 polymorphism and susceptibility for SARS-CoV-2 infection and severity of COVID-19.
Möhlendick B; Schönfelder K; Breuckmann K; Elsner C; Babel N; Balfanz P; Dahl E; Dreher M; Fistera D; Herbstreit F; Hölzer B; Koch M; Kohnle M; Marx N; Risse J; Schmidt K; Skrzypczyk S; Sutharsan S; Taube C; Westhoff TH; Jöckel KH; Dittmer U; Siffert W; Kribben A
Pharmacogenet Genomics; 2021 Oct; 31(8):165-171. PubMed ID: 34001841
[TBL] [Abstract][Full Text] [Related]
31. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
Kuba K; Yamaguchi T; Penninger JM
Front Immunol; 2021; 12():732690. PubMed ID: 35003058
[TBL] [Abstract][Full Text] [Related]
32. COVID-19 severity in obese patients: Potential mechanisms and molecular targets for clinical intervention.
Sharma JR; Yadav UCS
Obes Res Clin Pract; 2021; 15(2):163-171. PubMed ID: 33509701
[TBL] [Abstract][Full Text] [Related]
33. The Weight of Obesity in Immunity from Influenza to COVID-19.
Andrade FB; Gualberto A; Rezende C; Percegoni N; Gameiro J; Hottz ED
Front Cell Infect Microbiol; 2021; 11():638852. PubMed ID: 33816341
[TBL] [Abstract][Full Text] [Related]
34. COVID-19 and diabetes mellitus: from pathophysiology to clinical management.
Lim S; Bae JH; Kwon HS; Nauck MA
Nat Rev Endocrinol; 2021 Jan; 17(1):11-30. PubMed ID: 33188364
[TBL] [Abstract][Full Text] [Related]
35. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
[TBL] [Abstract][Full Text] [Related]
36. SARS-CoV-2 Infection in the Central and Peripheral Nervous System-Associated Morbidities and Their Potential Mechanism.
Karuppan MKM; Devadoss D; Nair M; Chand HS; Lakshmana MK
Mol Neurobiol; 2021 Jun; 58(6):2465-2480. PubMed ID: 33439437
[TBL] [Abstract][Full Text] [Related]
37. ACE2 function in the pancreatic islet: Implications for relationship between SARS-CoV-2 and diabetes.
Memon B; Abdelalim EM
Acta Physiol (Oxf); 2021 Dec; 233(4):e13733. PubMed ID: 34561952
[TBL] [Abstract][Full Text] [Related]
38. The COVID-19 Effect on the Immune System and Mitochondrial Dynamics in Diabetes, Obesity, and Dementia.
Holder K; Reddy PH
Neuroscientist; 2021 Aug; 27(4):331-339. PubMed ID: 32981462
[TBL] [Abstract][Full Text] [Related]
39. SARS-CoV-2 perturbs the renin-angiotensin system and energy metabolism.
Mori J; Oudit GY; Lopaschuk GD
Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E43-E47. PubMed ID: 32469255
[TBL] [Abstract][Full Text] [Related]
40. Going viral in the islet: mediators of SARS-CoV-2 entry beyond ACE2.
Rangu R; Wander PL; Barrow BM; Zraika S
J Mol Endocrinol; 2022 Jun; 69(2):R63-R79. PubMed ID: 35521990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
